Shuping Guo

机构：Shanxi Medical University, First Hospital of Shanxi Medical University, Ningxia Medical University, Ningxia Medical University General Hospital · ORCID：0009-0006-9634-8432

发表论文 78 篇 · 总被引 482 次 · h-index 11

代表论文

• Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial (2024 · British Journal of Dermatology · 被引 17)
• Efficacy and safety of SYSA1902 versus reference ustekinumab in moderate-to-severe plaque psoriasis: A multicenter, randomized, phase III study (2025 · Journal of the American Academy of Dermatology · 被引 7)
• Paradoxical Behçet’s Disease after Ixekizumab: A Case Report and Literature Review (2024 · Indian Journal of Dermatology · 被引 7)
• Prognostic value of TNF-α, PCT, IL-8, and HBP, combined with APACHE II score in patients with sepsis (2025 · The Journal of Infection in Developing Countries · 被引 6)
• Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient‐Reported Outcomes in a Randomized Trial (2025 · The Journal of Dermatology · 被引 3)
• Exploring disease perception and experiences of postoperative patients with Stanford type A aortic dissection: a qualitative study (2025 · BMC Cardiovascular Disorders · 被引 3)